A randomised controlled trial to evaluate the efficacy of a 6 month dietary and physical activity intervention in prostate cancer patients receiving androgen deprivation therapy
Dr. Roisin O’Neill (CoEfPHNI)
10.30, Tuesday 9 July. The Clubhouse, level 4
Androgen Deprivation Therapy (ADT) use in prostate cancer patients is associated with adverse side effects including: changes in body composition; an increase in fat mass and a decrease in muscle mass, increased fatigue and a reduced quality of life (QoL). The aim of this study was to test the efficacy of a combined 6-month diet and physical activity intervention to reduce the side effects associated with ADT.
Prostate cancer patients receiving ADT were randomly assigned to either an intervention arm to receive individualised healthy eating advice plus physical activity advice (to achieve 30 minutes of brisk walking per day, 5 or more days per week) (n=47) or a standard care control arm (n=47). Baseline, 3 month and 6 month assessments included Body Mass Index (BMI), percentage fat mass, waist circumference, functional capacity (6 minute walk test), fatigue, QoL, and perceived stress scores.
At 6 months, weight, BMI and percentage fat mass decreased significantly (p<0.001) in the intervention arm compared with the control arm; the between group differences (adjusted for baseline values) were -3.3kg (95% CI -4.5, -2.1), -1.1kg/m2 (95% CI-1.5,-0.7) and -2.1% (95% CI-2.8,-1) respectively. Waist circumference decreased and functional capacity increased in the intervention group compared to the control group; the between group differences were -3.3cm (95% CI-4.6, -1.9) (P=0.009) and +36.5m (95% CI 14.5, 58.4) (p <0.001) respectively. Improvements in fatigue, QoL and stress scores were also shown but were not statistically significant.
This intervention has proven beneficial at reducing the body composition changes associated with ADT. It would therefore be prudent to advise prostate cancer patients who begin ADT to modify their diet and lifestyle to help reduce these side effects.
Prostate cancer patients receiving ADT were randomly assigned to either an intervention arm to receive individualised healthy eating advice plus physical activity advice (to achieve 30 minutes of brisk walking per day, 5 or more days per week) (n=47) or a standard care control arm (n=47). Baseline, 3 month and 6 month assessments included Body Mass Index (BMI), percentage fat mass, waist circumference, functional capacity (6 minute walk test), fatigue, QoL, and perceived stress scores.
At 6 months, weight, BMI and percentage fat mass decreased significantly (p<0.001) in the intervention arm compared with the control arm; the between group differences (adjusted for baseline values) were -3.3kg (95% CI -4.5, -2.1), -1.1kg/m2 (95% CI-1.5,-0.7) and -2.1% (95% CI-2.8,-1) respectively. Waist circumference decreased and functional capacity increased in the intervention group compared to the control group; the between group differences were -3.3cm (95% CI-4.6, -1.9) (P=0.009) and +36.5m (95% CI 14.5, 58.4) (p <0.001) respectively. Improvements in fatigue, QoL and stress scores were also shown but were not statistically significant.
This intervention has proven beneficial at reducing the body composition changes associated with ADT. It would therefore be prudent to advise prostate cancer patients who begin ADT to modify their diet and lifestyle to help reduce these side effects.